Human Erythropoietin/EPO Quantikine ELISA Kit, RUO

• Reactivity: Hu
• Applications: ELISA
• Conjugate: HRP

Human Erythropoietin/EPO Quantikine ELISA Kit, RUO Summary

• Background: The Quantikine® Human Epo ELISA uses a monoclonal antibody and polyclonal antibody conjugate in a sandwich ELISA format. The assay is designed to measure Epo levels in serum or EDTA plasma in less than 4.5 hours, or less than 2.5 hours using the shaker protocol.
• Specificity: Natural and recombinant human Epo.
• Source: N/A
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: Interference observed with other substances.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human Erythropoietin/EPO Quantikine ELISA Kit, RUO

• ECYT5
• EP
• EPO
• epoetin
• Erythropoietin
• MGC138142
• MVCD2

Background

Erythropoietin (Epo), a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of Epo is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of Epo in the circulation increases and this leads to increased production of red blood cells. 

The over-expression of Epo may be associated with certain pathophysiological conditions (1, 2). Polycythemia exists when there is an overproduction of red blood cells (RBCs). Primary polycythemias, such as polycythemia vera, are caused by Epo-independent growth of erythrocytic progenitors from abnormal stem cells and low to normal levels of Epo are found in the serum of affected patients. On the other hand, various types of secondary polycythemias are associated with the production of higher than normal levels of Epo. The overproduction of Epo may be an adaptive response associated with conditions that produce tissue hypoxia, such as living at high altitude, chronic obstructive pulmonary disease, cyanotic heart disease, sleep apnea, high-affinity hemoglobinopathy, smoking, or localized renal hypoxia (1, 2). In other instances, excessive Epo levels are the result of production by neoplastic cells. Cases of increased Epo production and erythrocytosis have been reported for patients with renal carcinomas (3), benign renal tumors (4), Wilms' tumors, hepatomas (5), liver carcinomas (6), cerebellar hemangioblastomas (3, 7, 8), adrenal gland tumors (9), smooth muscle tumors (3, 9), and leiomyomas (10). 

Deficient Epo production is found in conjunction with certain forms of anemias. These include anemia of renal failure and end-stage renal disease (1, 2, 11), anemias of chronic disorders [chronic infections (1), autoimmune diseases (1), rheumatoid arthritis (12), AIDS (13), malignancies (14)], anemia of prematurity (2), anemia of hypothyroidism (2), and anemia of malnutrition (2). Many of these conditions are associated with the generation of IL-1 and TNF-alpha , factors that have been shown to be inhibitors of Epo activity (1, 15). Other forms of anemias, on the other hand, are due to Epo-independent causes and affected individuals show elevated levels of Epo (2). These forms include aplastic anemias, iron deficiency anemias, thalassemias, megaloblastic anemias, pure red cell aplasias, and myelodysplastic syndromes.

⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Publications for Erythropoietin/EPO (DEPRU0)(4)

Publications using DEPRU0

• Shirane, D;Tanaka, H;Sakurai, Y;Taneichi, S;Nakai, Y;Tange, K;Ishii, I;Akita, H; Development of an Alcohol Dilution-Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability Pharmaceutics 2023-06-26 [PMID: 37514007] ( Human)
• Andrade, JF;Dalboni, MA;Clemente, OC;Silva, BM;Domingues, BF;Rodrigues, AM;Canziani, ME;Zarjou, A;Cendoroglo, M;Goes, MA; A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease PloS one 2023-06-30 [PMID: 37390095] (Human)
• Alexandre Marchand, Geoff Miller, Laurent Martin, Coralie Gobbo, Andre K. Crouch, Daniel Eichner et al. Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes Drug Testing and Analysis 2022-11-01 [PMID: 35789123] (Human)
• PH Jaïs, E Decroly, E Jacquet, M Le Boulch, A Jaïs, O Jean-Jean, H Eaton, P Ponien, F Verdier, B Canard, S Goncalves, S Chiron, M Le Gall, P Mayeux, M Shmulevitz C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system Nucleic Acids Res., 2019-03-18;0(0):. 2019-03-18 [PMID: 30726994] (Transgenic Hamster)